Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT03712202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study identification
- NCT ID
- NCT03712202
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 155 participants
Conditions and interventions
Conditions
- Ann Arbor Stage I Hodgkin Lymphoma
- Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma
- Ann Arbor Stage IA Hodgkin Lymphoma
- Ann Arbor Stage IB Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Lymphocyte-Rich Classic Hodgkin Lymphoma
- Ann Arbor Stage I Lymphocyte-Depleted Classic HL
- Ann Arbor Stage II Lymphocyte-Depleted Classic HL
- Ann Arbor Stage II Mixed Cellularity Classic HL
- Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions
- Bleomycin Drug
- Brentuximab Vedotin Drug
- Dacarbazine Drug
- Doxorubicin Drug
- Nivolumab Biological
- Quality-of-Life Assessment Other
- Vinblastine Drug
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2018 (Actual)
- Primary completion
- Dec 23, 2024 (Estimated)
- Completion
- Dec 23, 2024 (Estimated)
- Last update posted
- Nov 6, 2024
2018 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03712202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2024 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03712202 live on ClinicalTrials.gov.